294 related articles for article (PubMed ID: 38177560)
61. Cholangiocarcinoma.
Patel T
Nat Clin Pract Gastroenterol Hepatol; 2006 Jan; 3(1):33-42. PubMed ID: 16397610
[TBL] [Abstract][Full Text] [Related]
62. Defining the role of adjuvant therapy: cholangiocarcinoma and gall bladder cancer.
Williams TM; Majithia L; Wang SJ; Thomas CR
Semin Radiat Oncol; 2014 Apr; 24(2):94-104. PubMed ID: 24635866
[TBL] [Abstract][Full Text] [Related]
63. Targeted Therapies for Perihilar Cholangiocarcinoma.
Gray S; Lamarca A; Edeline J; Klümpen HJ; Hubner RA; McNamara MG; Valle JW
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406560
[TBL] [Abstract][Full Text] [Related]
64. [Therapeutic advances in the management of biliary tract carcinoma].
Ribiere SC; Léandri C; Guillaumot MA; Brezault C; Coriat R
Presse Med; 2018 May; 47(5):419-422. PubMed ID: 29622390
[TBL] [Abstract][Full Text] [Related]
65. Surgery and hepatic artery infusion therapy for intrahepatic cholangiocarcinoma.
Scott A; Wong P; Melstrom LG
Surgery; 2023 Jul; 174(1):113-115. PubMed ID: 36906437
[TBL] [Abstract][Full Text] [Related]
66. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
67. Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer.
Skipworth JR; Olde Damink SW; Imber C; Bridgewater J; Pereira SP; Malagó M
Aliment Pharmacol Ther; 2011 Nov; 34(9):1063-78. PubMed ID: 21933219
[TBL] [Abstract][Full Text] [Related]
68. Advances in immunotherapy for biliary tract cancers.
Zhao Y; Yang M; Feng J; Wang X; Liu Y
Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
[TBL] [Abstract][Full Text] [Related]
69. Hilar cholangiocarcinoma: expert consensus statement.
Mansour JC; Aloia TA; Crane CH; Heimbach JK; Nagino M; Vauthey JN
HPB (Oxford); 2015 Aug; 17(8):691-9. PubMed ID: 26172136
[TBL] [Abstract][Full Text] [Related]
70. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience.
Gusani NJ; Balaa FK; Steel JL; Geller DA; Marsh JW; Zajko AB; Carr BI; Gamblin TC
J Gastrointest Surg; 2008 Jan; 12(1):129-37. PubMed ID: 17851723
[TBL] [Abstract][Full Text] [Related]
71. NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
Maithel SK; Keilson JM; Cao HST; Rupji M; Mahipal A; Lin BS; Javle MM; Cleary SP; Akce M; Switchenko JM; Rocha FG
Ann Surg Oncol; 2023 Oct; 30(11):6558-6566. PubMed ID: 37368098
[TBL] [Abstract][Full Text] [Related]
72. Surgery of extrahepatic bile duct cancer - current evidence and recommendations.
Nikov A; Gürlich R
Rozhl Chir; 2022; 101(9):416-420. PubMed ID: 36257799
[TBL] [Abstract][Full Text] [Related]
73. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee CK; Chon HJ; Cheon J; Lee MA; Im HS; Jang JS; Kim MH; Park S; Kang B; Hong M; Kim JW; Park HS; Kang MJ; Park YN; Choi HJ
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):56-65. PubMed ID: 36328033
[TBL] [Abstract][Full Text] [Related]
74. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study.
Kato A; Shimizu H; Ohtsuka M; Yoshidome H; Yoshitomi H; Furukawa K; Takeuchi D; Takayashiki T; Kimura F; Miyazaki M
Ann Surg Oncol; 2013 Jan; 20(1):318-24. PubMed ID: 23149849
[TBL] [Abstract][Full Text] [Related]
75. Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes.
Waseem D; Tushar P
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):133-139. PubMed ID: 28051802
[TBL] [Abstract][Full Text] [Related]
76. Will advanced cholangiocarcinoma become a targetable malignancy?
Sarkis Y; Al Soueidy A; Kourie HR
Crit Rev Oncol Hematol; 2021 Mar; 159():103233. PubMed ID: 33482346
[TBL] [Abstract][Full Text] [Related]
77. NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.
Benson AB; D'Angelica MI; Abrams T; Abbott DE; Ahmed A; Anaya DA; Anders R; Are C; Bachini M; Binder D; Borad M; Bowlus C; Brown D; Burgoyne A; Castellanos J; Chahal P; Cloyd J; Covey AM; Glazer ES; Hawkins WG; Iyer R; Jacob R; Jennings L; Kelley RK; Kim R; Levine M; Palta M; Park JO; Raman S; Reddy S; Ronnekleiv-Kelly S; Sahai V; Singh G; Stein S; Turk A; Vauthey JN; Venook AP; Yopp A; McMillian N; Schonfeld R; Hochstetler C
J Natl Compr Canc Netw; 2023 Jul; 21(7):694-704. PubMed ID: 37433432
[TBL] [Abstract][Full Text] [Related]
78. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment.
Cholangiocarcinoma Working Group
Dig Liver Dis; 2020 Dec; 52(12):1430-1442. PubMed ID: 32952071
[TBL] [Abstract][Full Text] [Related]
79. The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines.
Fong ZV; Brownlee SA; Qadan M; Tanabe KK
Ann Surg Oncol; 2021 May; 28(5):2660-2674. PubMed ID: 33646431
[TBL] [Abstract][Full Text] [Related]
80. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
